Next Article in Journal
Association of Genetic Polymorphisms of Renin–Angiotensin–Aldosterone System-Related Genes with Arterio-Venous Fistula Malfunction in Hemodialysis Patients
Next Article in Special Issue
Melanoma Cells Can Adopt the Phenotype of Stromal Fibroblasts and Macrophages by Spontaneous Cell Fusion in Vitro
Previous Article in Journal
Fast Modeling of Binding Affinities by Means of Superposing Significant Interaction Rules (SSIR) Method
Previous Article in Special Issue
Hybrid Cells Derived from Human Breast Cancer Cells and Human Breast Epithelial Cells Exhibit Differential TLR4 and TLR9 Signaling
Article Menu
Issue 6 (June) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2016, 17(6), 828;

Dendritic-Tumor Fusion Cell-Based Cancer Vaccines

Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Kashiwa Hospital, 277-8567 Chiba, Japan
Academic Editor: Thomas Dittmar
Received: 14 May 2016 / Revised: 19 May 2016 / Accepted: 23 May 2016 / Published: 26 May 2016
(This article belongs to the Special Issue Cell Fusion in Cancer)
Full-Text   |   PDF [4269 KB, uploaded 26 May 2016]   |  


Dendritic cells (DCs) are potent antigen-presenting cells (APCs) that play a critical role in the induction of antitumor immunity. Therefore, various strategies have been developed to deliver tumor-associated antigens (TAAs) to DCs as cancer vaccines. The fusion of DCs and whole tumor cells to generate DC-tumor fusion cells (DC-tumor FCs) is an alternative strategy to treat cancer patients. The cell fusion method allows DCs to be exposed to the broad array of TAAs originally expressed by whole tumor cells. DCs then process TAAs endogenously and present them through major histocompatibility complex (MHC) class I and II pathways in the context of costimulatory molecules, resulting in simultaneous activation of both CD4+ and CD8+ T cells. DC-tumor FCs require optimized enhanced immunogenicity of both DCs and whole tumor cells. In this context, an effective fusion strategy also needs to produce immunogenic DC-tumor FCs. We discuss the potential ability of DC-tumor FCs and the recent progress in improving clinical outcomes by DC-tumor FC-based cancer vaccines. View Full-Text
Keywords: dendritic cell; whole tumor cell; cell fusions; cancer vaccines; cytotoxic T lymphocyte dendritic cell; whole tumor cell; cell fusions; cancer vaccines; cytotoxic T lymphocyte

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Koido, S. Dendritic-Tumor Fusion Cell-Based Cancer Vaccines. Int. J. Mol. Sci. 2016, 17, 828.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top